79 terminated. 79 Phase 1, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 79 | Terminated 79 |
| Phase 2 | 26 | Terminated 26 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis OTC Drug for Atopic Dermatitis in Cream form - Atopic Dermatitis (AD) | Phase 1 | Terminated | Good Molecules, LLC | 3 | 2025-08-14 | 2026-05-27 |
| A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma Briquilimab, Placebo Comparator - Allergic Asthma | Phase 1 | Terminated | Jasper Therapeutics, Inc. | 17 | 2024-11-26 | 2025-09-16 |
| Topical ENS-002 for Atopic Dermatitis in Adults ENS-002 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Terminated | Concerto Biosciences | 9 | 2024-09-18 | 2025-08-14 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 27 | 2024-03-18 | 2025-10-08 |
| A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis LY3872386, Prednisone, Placebo - Healthy, Atopic Dermatitis | Phase 1 | Terminated | Eli Lilly and Company | 18 | 2023-11-01 | 2025-10-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Mometasone + Azelastine, Mometasone Furoate, Azelastine Hydrochloride - Seasonal Allergic Rhinitis | Phase 1 | Terminated | Sandoz | 38 | 2023-06-08 | 2023-09-28 |
| Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) NM26-2198, Placebo - Atopic Dermatitis | Phase 1 | Terminated | Yellow Jersey Therapeutics AG | 126 | 2023-05-10 | 2026-07-06 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis XmAb27564, Placebo - Psoriasis, Atopic Dermatitis | Phase 1 | Terminated | Xencor, Inc. | 23 | 2022-10-10 | 2025-12-02 |
| To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis TQC3564 tablets, Placebo tablets, TQC3564 tablets, montelukast sodium tablets - Allergic Rhinitis | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 12 | 2022-09-14 | 2024-11-26 |
| A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis LY3844583, Placebo - Healthy, Dermatitis, Atopic | Phase 1 | Terminated | Eli Lilly and Company | 86 | 2022-08-11 | 2026-10-13 |
| Targeted Investigation of Microbiome Elimination S. hominis A 9 Product, Placebo - Atopic Dermatitis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2022-07-18 | 2024-11-12 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| A Study of Orally Administered IPG7236 in Healthy Adult Participants IPG7236- Single ascending dose, IPG7236- Multiple ascending dose, Placebo (Part A) - Atopic Dermatitis | Phase 1 | Terminated | Nanjing Immunophage Biotech Co., Ltd | 63 | 2022-04-07 | 2025-12-22 |
| Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone - Asthma | Phase 1 | Terminated | Emory University | 1 | 2022-03-16 | 2025-06-03 |
| Open-label Extension Study of ADP101 ADP101 - Food Allergy | Phase 1 / Phase 2 | Terminated | Alladapt Immunotherapeutics, Inc. | 45 | 2022-03-14 | 2024-03-26 |
| CNP-201 in Subjects With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 15 | 2022-03-14 | 2023-12-20 |
| Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma Zavegepant, Placebo - Asthma | Phase 1 | Terminated | Pfizer | 45 | 2021-10-18 | 2024-07-19 |
| First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 LQ036, Matching Placebo - Asthma | Phase 1 | Terminated | Syneos Health | 40 | 2021-09-06 | 2023-04-13 |
| A Trial of SHR-1703 in Healthy Subjects SHR-1703, Placebo - Asthma | Phase 1 | Terminated | Atridia Pty Ltd. | 1 | 2021-06-14 | 2021-12-01 |
Showing 20 of 79. Sign in to see all of them.
Asthma (32) · Dermatitis, Atopic (20) · Peanut Hypersensitivity (6) · Urticaria (6) · Food Hypersensitivity (5) · Eczema (4) · Immune System Diseases (4) · Rhinitis, Allergic (4) · Chronic Urticaria (3) · Skin Diseases (3) · Chronic Inducible Urticaria (2) · Conjunctivitis, Allergic (2) · Dermatitis (2) · Hypersensitivity, Immediate (2)
Immune System Diseases (75) · Hypersensitivity, Immediate (71) · Respiratory Tract Diseases (38) · Respiratory Hypersensitivity (37) · Lung Diseases (33) · Bronchial Diseases (31) · Lung Diseases, Obstructive (31) · Skin and Connective Tissue Diseases (28) · Skin Diseases (25) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Genetic Diseases, Inborn (23) · Skin Diseases, Genetic (21) · Skin Diseases, Eczematous (20) · Dermatitis (19)
Epinephrine (2) · Interleukin 1 Receptor Antagonist Protein (2) · Prednisolone (2) · Prednisone (2) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (1) · ASM-024 (1) · Albuterol (1) · Antigens, Dermatophagoides (1) · Asparaginase (1) · BASS2 protein, Arabidopsis (1) · Bronchoscopy (1) · Calcium Dobesilate (1) · Capsules (1) · Cetirizine (1) · Clobetasol (1)
GlaxoSmithKline (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Amphastar Pharmaceuticals, Inc. (2) · AstraZeneca (2) · COUR Pharmaceutical Development Company, Inc. (2) · Eli Lilly and Company (2) · Jasper Therapeutics, Inc. (2) · John Sundy (2) · Johns Hopkins University (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · 4D pharma plc (1) · AKARI Therapeutics (1) · AbbVie (1) · Alladapt Immunotherapeutics, Inc. (1)
United States (44) · United Kingdom (11) · Canada (9) · Germany (8) · Australia (5) · Japan (3) · Poland (3) · Spain (3) · South Korea (2) · Switzerland (2) · Belgium (1) · Bulgaria (1) · China (1) · Finland (1) · France (1)
Jerry Staser (2) · Alessio Fasano, M. D. (1) · Barry J. Byrne, MD, PhD (1) · Bernardo Cervantes, PhD (1) · Calman P Prussin, M.D. (1) · Christopher Brightling, Professor (1) · Christopher O'Brien, MD, PhD, FCCP (1) · Clifton O. Bingham, III, MD (1)
PMID 29550052, PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 18645136, PMID 22294344, PMID 25223501, PMID 27143789, PMID 28118536, PMID 32150492, PMID 33293212, PMID 33314326, PMID 35128939
2023 (3), 2018 (2), 2019 (2), 2015 (1), 2017 (1), P01AT002647 (1), R01HL079184 (1), R21AT004089 (1), ZIAAR041138-08 (1)